|
Gene: MZT2A |
Gene summary for MZT2A |
Gene summary. |
Gene information | Species | Human | Gene symbol | MZT2A | Gene ID | 653784 |
Gene name | mitotic spindle organizing protein 2A | |
Gene Alias | FAM128A | |
Cytomap | 2q21.1 | |
Gene Type | protein-coding | GO ID | GO:0000930 | UniProtAcc | Q6P582 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
653784 | MZT2A | C09 | Human | Oral cavity | OSCC | 5.76e-09 | 6.55e-01 | 0.1431 |
653784 | MZT2A | LN22 | Human | Oral cavity | OSCC | 8.37e-22 | 2.28e+00 | 0.1733 |
653784 | MZT2A | LN38 | Human | Oral cavity | OSCC | 3.14e-20 | 2.65e+00 | 0.168 |
653784 | MZT2A | LN46 | Human | Oral cavity | OSCC | 5.23e-28 | 1.79e+00 | 0.1666 |
653784 | MZT2A | LP15 | Human | Oral cavity | LP | 1.77e-16 | 2.83e+00 | 0.2174 |
653784 | MZT2A | LP17 | Human | Oral cavity | LP | 7.10e-14 | 2.03e+00 | 0.2349 |
653784 | MZT2A | SYSMH1 | Human | Oral cavity | OSCC | 2.01e-36 | 1.27e+00 | 0.1127 |
653784 | MZT2A | SYSMH2 | Human | Oral cavity | OSCC | 5.46e-41 | 1.97e+00 | 0.2326 |
653784 | MZT2A | SYSMH3 | Human | Oral cavity | OSCC | 3.06e-42 | 1.83e+00 | 0.2442 |
653784 | MZT2A | SYSMH4 | Human | Oral cavity | OSCC | 2.77e-29 | 8.25e-01 | 0.1226 |
653784 | MZT2A | SYSMH5 | Human | Oral cavity | OSCC | 4.27e-13 | 7.14e-01 | 0.0647 |
653784 | MZT2A | SYSMH6 | Human | Oral cavity | OSCC | 4.77e-22 | 1.17e+00 | 0.1275 |
653784 | MZT2A | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 2.13e-03 | 3.74e-01 | -0.1972 |
653784 | MZT2A | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 2.35e-13 | 6.03e-01 | -0.2126 |
653784 | MZT2A | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 2.78e-07 | 4.96e-01 | -0.23 |
653784 | MZT2A | 047563_1562-all-cells | Human | Prostate | BPH | 4.30e-26 | -3.51e-01 | 0.0791 |
653784 | MZT2A | 052095_1628-all-cells | Human | Prostate | BPH | 9.97e-05 | -3.12e-01 | 0.1032 |
653784 | MZT2A | 052097_1595-all-cells | Human | Prostate | BPH | 3.07e-02 | -2.64e-01 | 0.0972 |
653784 | MZT2A | 052099_1652-all-cells | Human | Prostate | BPH | 4.23e-06 | -3.30e-01 | 0.1038 |
653784 | MZT2A | Dong_P1 | Human | Prostate | Tumor | 2.28e-32 | 4.40e-01 | 0.035 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MZT2A | SNV | Missense_Mutation | c.455G>A | p.Ser152Asn | p.S152N | Q6P582 | protein_coding | tolerated_low_confidence(0.21) | probably_damaging(0.954) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MZT2A | SNV | Missense_Mutation | rs377259626 | c.370C>T | p.Arg124Cys | p.R124C | Q6P582 | protein_coding | tolerated(0.08) | benign(0.022) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MZT2A | SNV | Missense_Mutation | c.319N>T | p.Gly107Trp | p.G107W | Q6P582 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DD-AACF-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MZT2A | SNV | Missense_Mutation | novel | c.466G>T | p.Gly156Cys | p.G156C | Q6P582 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.671) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD |
MZT2A | SNV | Missense_Mutation | c.364N>T | p.Ala122Ser | p.A122S | Q6P582 | protein_coding | tolerated(0.29) | benign(0.202) | TCGA-22-4613-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MZT2A | SNV | Missense_Mutation | novel | c.442N>T | p.Gly148Trp | p.G148W | Q6P582 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-37-3792-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MZT2A | SNV | Missense_Mutation | novel | c.464A>T | p.Gln155Leu | p.Q155L | Q6P582 | protein_coding | deleterious_low_confidence(0.01) | benign(0.007) | TCGA-68-7755-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unspecific | SD | |
MZT2A | SNV | Missense_Mutation | c.402G>A | p.Met134Ile | p.M134I | Q6P582 | protein_coding | tolerated(0.14) | benign(0.026) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MZT2A | SNV | Missense_Mutation | rs867572181 | c.403C>T | p.Pro135Ser | p.P135S | Q6P582 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-CG-5723-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |